Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept dose finding in beta-thalassemia
NCT01571635Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2012
- Primary completion
- Jul 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of sotatercept in beta thalassemia, sponsored by Celgene Corporation. Started Oct 2012; status: terminated.
02
Drugs
sotatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT01571635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571635.